Pressrelease

Uppsala 17th December 2018

Nanexa enters into agreements with world-leading animal health companies

Late Friday night, Nanexa signed a commercial evaluation agreement, a so-called “material transfer and feasibility study agreement”, with a world-leading global animal health company.

The company, which has its headquarters in the United States, will, within the framework of the agreement, evaluate PharmaShell® for a specific combination product. It is the properties of PharmaShells® that make it possible to create really long depot products that have been in demand by the American company.

The agreement means that Nanexa will coat the company’s active substances with PharmaShell® and in turn they will evaluate the effect of this in relevant models for their intended product development. The product they aim to develop with PharmaShell® is for a significant indication and is planned to be used for several animal species. The global animal health market is valued at $ 42.2 billion with annual growth of 5.5% according to Grand View Research, June 2018.

The Animal-Health Company is responsible for all costs for evaluation and Nanexa receives an agreed minor compensation for the delivery of coated material.

 

The company’s CEO David Westberg comments:

“I am very pleased that we have now signed a commercial agreement with a large global company in the attractive animal health industry. This is a big step in the right direction for Nanexa.”

 

For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail: david.westberg@nanexa.se

www.nanexa.com

 

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.